Celebrex Cardiovascular Safety Trial Will Allow Acetaminophen Use
This article was originally published in The Tan Sheet
Executive Summary
Pfizer believes that allowing patients to take non-NSAID pain relievers, such as acetaminophen, in a trial evaluating the cardiovascular risk profile of Celebrex (celecoxib) will make a long-term placebo-controlled study in the arthritis population feasible
You may also be interested in...
Merck Defends Inaction on Vioxx VIGOR Data, Cites Naproxen Heart Benefit
Merck continues to support the cardioprotective effect of the non-steroidal anti-inflammatory drug naproxen
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)
NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts